The under-13s were the second Meninos da Vila team to secure a place in the quarterfinals of the Campeonato Paulista! They beat RB Bragantino again, this time 5–1 at CT Rei Pelé, with two goals from Davi Lucas and one each from Guilherme Henrique, Enzo Donizete and Kauan Lisboa!
Having won the first leg 1–0, they advanced 6–1 on aggregate and now await their next opponents.
At under-14 level, another win and another qualification for the Meninos da Vila! The team thrashed EC São Bernardo 5–0 at CT Rei Pelé on Sunday afternoon (18) to secure a place in the quarterfinals! Peixe advanced 6–0 on aggregate!
Felipe Rafael scored twice, with Kauan Basile, Phelipe Thomas and Madson Matos also finding the net for Peixe.
The team now also awaits confirmation from the FPF to find out who their next opponents will be!

#kauan #place

Ukraine on Thursday accused Russia of deliberately targeting civilians after 30 people were killed when two buses were blown up in the frontline city of Kramatorsk, in one of the deadliest single attacks for weeks.
Photos posted by local authorities showed the burnt-out metal shell of the vehicles, with the blurred-out images of bodies and debris strewn across the road.
Police said the buses were hit with a glide bomb.
The strikes come just a day after five children were among 22 killed when a Russian missile struck a five-storey apartment block in Pryluky, in the northern Chernigiv region.
"The Russians are deliberately targeting civilians," Donetsk Governor Vadym Filashkin said, accusing Moscow of flouting "every conceivable rule of warfare and norm of international humanitarian law".

#targeting #civilians #Russia

The BBC has "apologized unreservedly for the defamatory allegations" made in a documentary and accompanying article about the founder of one of the UK's leading LGBTQ+ publications and his husband.
The BBC this morning removed from its website the original PinkNews article. The documentary came off iPlayer last year after its window ran down.
More from Deadline
BBC Boss Matt Brittin Sets Out Silicon Valley-Style Revolution At British Broadcaster
'Doctor Who' Bids Revealed: Jed Mercurio Leads Pitch To Regenerate BBC Series, As STV Studios Plans To Transport TARDIS To Scotland

#pinknews

The Princess of Wales is always poised, elegant and professional during her royal engagements, and she kept her composure even when subtly asking the press to step backwards as she walked by amid an engagement in Norfolk.
It was in June 2020, when COVID-19 restrictions were still in place, that Kate, who was then the ***** ss of Cambridge, made her first face-to-face public engagement since lockdown began. The royal visited Fakenham Garden Centre near her country home, Anmer Hall, and she was seen holding her hands up to distance herself from the press amid the 'two-meter rule'.
Kate adhered to the two metre rule implemented by the UK government (@ Photo: Getty Images)
She could be heard saying: "Hello, how are you? This is two meters," as she moved slightly away from them and stretched out her hands. She then headed to greet employees of the centre, again at a safe distance.
During the visit, Kate shared that her children, Prince George, Princess Charlotte, and Prince Louis, all love visiting garden centres. She also highlighted their enthusiasm for gardening at home, revealing that George enjoys playing with Venus flytraps and that all three children were thrilled to grow tomato plants from seeds, and they grew as tall as the young royals themselves.

#prince #press

Famous pals Tom Cruise and David Beckham share plenty of interests, says a source, including a love of beauty treatments.
"They're both obsessed with skincare," the source tells the National Enquirer. "Not a lot of men are as passionate about it as they are, so it's something that they've really bonded over."
According to the source, the retired athlete, 51, and the Top Gun star, 64, aren't simply trading grooming tips, either.
"Tom and David have been going for facials together," spills the source. "They've both gotten some pretty intense laser treatments too."
Thanks to the former soccer pro's wife, Victoria Beckham, "they have the numbers for all the best dermatologists and estheticians and hairstylists," adds the source. "And they have been putting them to use."

#cruise #they 're #enquirer

Wolfe Research upgraded two prominent pharmaceutical companies to Outperform on August 13. The firm upgraded both Biogen Inc. (NASDAQ:BIIB) and AbbVie Inc. (NYSE:ABBV)'s ratings from Peer Perform, with Wolfe ***** igning them similar $300 price targets. The firm's logic in each case was based on a comparable set of factors: pipelines that the market appears to undervalue, and valuations that Wolfe believes are too low given each company's growth track.
Wolfe's thesis for Biogen Inc. (NASDAQ:BIIB) is mainly based on late-stage clinical programs, which it believes the stock has yet to reflect. The firm focused on two experimental therapies in particular, both of which have key late-stage clinical readouts expected over the coming year: litifilimab, which Wolfe believes could be the first biologic approved for cutaneous lupus erythematosus, and felzartamab, which the firm claims represents a bigger commercial opportunity in antibody-mediated transplant rejection than Wall Street currently thinks.
Wolfe also cited Biogen's acquisition of Apellis Pharmaceuticals as strengthening its near-term revenue base through the FDA-approved drugs Empaveli and Syfovre. That move is part of an overall pattern of Biogen Inc. (NASDAQ:BIIB) diversifying beyond its core neurology brand, with the company completing its acquisition of RayThera on August 6, adding another early-stage immunology platform to its pipeline.
Wolfe's Biogen Inc. (NASDAQ:BIIB) thesis is incomplete without valuation. The firm believes the stock is trading at a discount to the broader market, despite the company's development on Leqembi, its Alzheimer's medication, and what Wolfe described as solid commercial execution overall.
AbbVie's upgrade is based on a slightly different premise: patent strength and cash generation rather than simple clinical events. Wolfe stated that AbbVie's 2027 earnings multiple of 14.6x seemed too low for a company that forecasts high-single-digit revenue growth for the rest of the decade. AbbVie's patent position, according to Wolfe, sets the company apart from its competitors in a way that the market has yet to completely price in.

#wolfe #firm #market #clinical

When it comes to long-term success with dividend investing, you need to focus on criteria beyond just yield. While some high yield dividend stocks can be worth the risk, there are plenty that are trading at a high yield for a good reason.
That is, either they are at risk of cutting or suspending their payouts, and/or other risks may lead to stock price declines that outweigh the returns generated by their large payouts. So, instead of focusing on yield alone, consider criteria such as dividend coverage and dividend growth, along with metrics like valuation.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Taking all of these into account, three blue chip dividend stocks stand out as strong, dare I say, "no brainer," buys right now: AbbVie (NYSE: ABBV), Realty Income (NYSE: O), and Procter & Gamble (NYSE: PG).
Several years ago, uncertainty ran high about AbbVie, mostly due to concerns about the impact of losing patent exclusivity for its flagship drug product, the rheumatoid arthritis treatment Humira. Yet while this did hurt AbbVie's revenue and earnings after exclusivity ended in 2023, the company has staged a comeback, largely thanks to the success of the anti-inflammatory drugs Skyrizi and Rinvoq.

#NYSE #abbvie #flashing

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) could be positioning itself for its next major phase of growth following its roughly $10 billion acquisition of Crinetics Pharmaceuticals. The deal gives the company immediate exposure to the endocrinology market and provides a new commercial platform beyond its established cystic fibrosis franchise.
On September 3, Citigroup **** yst Geoff Meacham highlighted the strategic importance of the Crinetics acquisition, arguing it could diversify Vertex's business while complementing its existing cystic fibrosis franchise and newer businesses in renal disease, hematology, and pain.
Through the transaction, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) gains access to Palsonify (paltusotine), an oral treatment for acromegaly that has already received regulatory approval in Europe. Paltusotine is also in Phase 3 development for carcinoid syndrome **** ociated with neuroendocrine tumors.
Palsonify is particularly important because it provides an immediate commercial revenue opportunity, rather than requiring the company to wait several years for an entirely new drug to reach the market.
Early uptake of Palsonify has been encouraging, supported by expanding physician adoption and improving reimbursement coverage. If that momentum continues, the drug could become an important contributor to Vertex's revenue growth.

#palsonify

Vitor Matos believes 39-year-old Jamie Vardy is still capable of making a mark in the Championship as the former England striker eyes a Burnley debut at Swansea City.
Vardy is set to be named in the Clarets squad to visit the Swansea.com Stadium, having joined Burnley this week after departing Italian club Cremonese.
And Swansea head coach Matos believes the former Leicester City frontman, who scored 200 goals in 500 Foxes appearances, still has the tools to thrive in the second tier.
"He is someone who understands how to score goals," said Matos, who is 14 months younger than Vardy.
"He moves really well - he always did that. He has a lot of talent - his finishing skills are there.

#matos #still

Serena Williams turned a frightening childbirth experience into a pointed conversation about women's healthcare. The tennis legend said her ordeal showed her how widespread those struggles had become.
Williams revisited the experience during the Forbes Power Women's Summit on September 10. She also connected her advocacy to motherhood, entrepreneurship and the example she wanted to set for her daughters.
Williams told Forbes Executive Vice President Moira Forbes that she initially misunderstood the scale of the problem. "When I told my story, I didn't realize how many people could relate," she said. "Then I realized it's a women's problem." She later delivered her bluntest punchline about childbirth. "If men were giving birth, they would have sweets [and] like all kinds of medicines," Williams said. She joked that the healthcare problem "wouldn't be the same" otherwise.
The 44-year-old faced life-threatening complications after delivering Alexis Olympia in 2017. Doctors performed an emergency C-section before a coughing fit reopened her wound. Williams previously detailed the ordeal in a 2018 CNN opinion piece. Doctors discovered a large abdominal hematoma before she developed a pulmonary embolism.
The condition triggered a six-day medical battle and multiple surgeries. Williams said her doctor listened when she knew something had gone wrong. "I knew something was wrong with me and it was super important that I was heard," she said. She credited her doctor and nurses with helping save her life.

#problem #doctors #healthcare #ordeal

The pharmaceutical sector was hit with major pipeline news on September 1 when Novartis AG (NYSE:NVS) paused eight clinical trials of rap-cel, its experimental CAR-T cell therapy targeting autoimmune and neurological disorders. The suspension, effective August 24, followed three patient deaths caused by severe, life-threatening immune reactions (immune effector cell-associated hemophagocytic syndrome). Novartis is currently conducting a safety review alongside independent monitoring boards. Following the news, Bristol-Myers Squibb Company (NYSE:BMY) voluntarily paused trials for its competing CAR-T treatment, zola-cel, as a precautionary measure after detecting transient inflammatory side effects.
Looking at Q2 2026 earnings, Bristol Myers Squibb is currently demonstrating stronger financial momentum. Bristol-Myers Squibb Company (NYSE:BMY) reported total revenue of $13.0 billion, up 6% year over year, driven by a 15% increase in its Growth Portfolio to $7.6 billion, led by Opdivo, Qvantig, Reblozyl, and Camzyos. Non-GAAP EPS reached $2.04, while net income totaled $3.3 billion, or $4.2 billion on a non-GAAP basis. The company also raised its full-year 2026 revenue guidance from approximately $46.0–$47.5 billion to $49.0–$50.0 billion and increased its non-GAAP EPS outlook to $6.75–$7.00.
Novartis AG (NYSE:NVS), meanwhile, reported Q2 net sales of $14.4 billion, up 3% in U.S. dollars and 1% at constant currencies, supported by Kisqali and Kesimpta, which grew 43% and 32% at constant currencies, respectively. However, generic competition reduced growth by 14 percentage points, while core operating income remained flat at $5.9 billion and GAAP net income fell 19% to $3.3 billion. Novartis reaffirmed rather than raised its full-year guidance, calling for low single-digit sales growth and a low single-digit decline in core operating income.
Overall, Bristol Myers stands out as the stronger financial story this quarter, with its Growth Portfolio offsetting legacy patent-cliff pressures and supporting a guidance increase, while Novartis continues to contend with generic erosion weighing on earnings.
Novartis' bull case rests on strong double-digit growth from high-margin blockbusters such as Kisqali, Kesimpta, and Scemblix, supporting robust Q2 free cash flow of $5.6 billion. However, CAR-T safety setbacks could threaten a key pipeline platform, while intense generic competition has already reduced top-line growth by 14 percentage points.

#billion #novartis

On September 3, AbbVie Inc. (NYSE:ABBV) finalized its acquisition of clinical-stage biotech Apogee Therapeutics, Inc. (NASDAQ:APGE) for $135.11 per share in cash. The $10.9 billion buyouts immediately fold Apogee's promising inflammatory and immunology (I&I) pipeline into AbbVie's commercial engine. On the exact same day, AbbVie separately reported positive Phase 3 Cervino trial results for its bispecific T-cell engager, etentamig, in relapsed/refractory multiple myeloma. Together, the dual catalysts emphasize how mega-cap pharmaceutical giants are deploying cash flow from legacy franchises to lock in next-generation immunology and oncology ***** ets.
In Q2 2026, AbbVie Inc. (NYSE:ABBV) posted $16.99 billion in net revenue, up 10.2% year over year, while adjusted diluted EPS increased 22.9% to $3.65. Growth was driven by its immunology blockbusters, Skyrizi and Rinvoq, which generated $5.505 billion and $2.525 billion in revenue, respectively, representing growth of 24.4% and 24.5%. These gains more than offset the continued decline in Humira revenue, which fell 35.9% to $756 million amid biosimilar competition. AbbVie reiterated its full-year 2026 adjusted EPS guidance of $13.87–$14.07, including a $0.14 dilutive impact from the Apogee transaction.
As a clinical-stage biotech, Apogee Therapeutics, Inc. (NASDAQ:APGE) generated no product revenue in Q2 2026, while R&D expenses reached $67.3 million and G&A expenses totaled $24.3 million, resulting in a quarterly net loss of $85.9 million. Despite the cash burn, the company maintained a strong liquidity position, with $1.3 billion in cash and marketable securities, alongside a $1.3 billion non-dilutive credit collaboration with Blackstone Life Sciences to support Phase 3 trials of its lead ***** et, zumilokibart.
Financially, AbbVie is vastly superior in immediate cash generation and profitability, whereas Apogee represented pure clinical optionality backed by robust liquidity.
For AbbVie, acquiring Apogee's optimized antibody portfolio, including zumilokibart for atopic dermatitis, strengthens its post-Humira immunology franchise. Combined with internal R&D advances such as etentamig, which achieved statistically significant overall response rate and progression-free survival results in the Phase 3 Cervino study, along with an 87.9% 12-month overall survival rate, AbbVie demonstrates potential to sustain strong organic growth.

#phase #revenue #Growth

The U-20 team secured qualification for the 2nd round of the Copa do Brasil on Thursday afternoon (10) by defeating Cuiabá 4-3 in a penalty shootout in a single-leg match held at CT Rei Pelé! In regular time, the game ended 1-1, with a goal by Contreras!
Rodrigo Cézar, Diego Matos, Guilherme Cruz, and Pepê Fermino converted Santos' penalties, while goalkeeper João Pedro came up with a huge save!
Santos opened the scoring just 4 minutes in after a corner kick taken by Vinícius Fabri. Contreras' first header was saved by the goalkeeper, but he got on the rebound and headed it home to put his team in front.
Still in the first half, the Santos side had more chances to extend the lead, but failed to turn them into goals. In the second half, despite Santos still controlling the match, Cuiabá managed to equalize right at the end, taking the fight for qualification to penalties.
In the next round, Santos FC will face Palmeiras in October, with the date still to be confirmed.

#santos #cuiab #contreras #goalkeeper

Interested in AbbVie Inc.? Here are five stocks we like better.
SKYRIZI and RINVOQ remain AbbVie's main growth drivers, with additional opportunities in inflammatory bowel disease, vitiligo, alopecia and hidradenitis suppurativa. The company expects a subcutaneous SKYRIZI induction approval for Crohn's disease in the fourth quarter and plans further combination-therapy data.
AbbVie is advancing a broad pipeline, including the BCMA-directed cancer therapy etentamig, which showed strong early multiple-myeloma results and could support a rapid regulatory filing. Neuroscience programs such as bretisilocin for depression are also expected to deliver additional data this year.
The company is taking a selective approach to acquisitions and partnerships, having invested about $20 billion in roughly 30 transactions while increasing annual R&D spending toward $10 billion. Management maintained its outlook for high-single-digit annual revenue growth through the decade.
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It

#disease #company #Therapy

Our ***** ysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Performance was anchored by the 'Reimagined 200' stores, which outperformed the broader fleet by 80 basis points, validating the strategy of enhanced staffing and curated ***** ortments.
Bloomingdale's achieved its highest second-quarter sales volume in its 154-year history, driven by a 1,700 basis point step-change on a two-year stack as it captures market share in premium and luxury segments.
Management attributed the 9% increase in Average Unit Retail (AUR) to a deliberate shift toward 'fashion authority' positioning, prioritizing better/best brand tiers over high-volume, low-margin units.
The company successfully leveraged enterprise-wide capabilities, such as Macy's is leveraging its marketplace business to fill white-space opportunities, while dermatological skincare brands like SkinCeuticals drove growth at Bluemercury.

#volume #year #management #average

Biopharmaceutical leader Kiniksa Pharmaceuticals (KNSA) is approaching a new buy point in the wake of a strong quarterly sales report. That makes Kiniksa stock Thursday's pick for IBD 50 Growth Stocks To Watch from Investor's Business Daily.
Kiniksa develops and commercializes medicines for cardiovascular, autoimmune and autoinflammatory diseases. Its only drug, Arcalyst, treats recurrent pericarditis, a condition in which the sac protecting the heart, the pericardium, becomes inflamed. The risk of recurrence increases with each subsequent flare-up of pericarditis, according to the Arcalyst website.
The company expects to replace Arcalyst with a next-generation version, now called KPL-387, in 2028 or 2029.
While Arcalyst requires a weekly under-the-skin shot, KPL-387 is a monthly injection. KPL-387 sales are expected to start slow at $21.7 million in 2028, growing to $173.7 million, $486.3 million and $1.03 billion over the next three years.
During the second quarter, Arcalyst generated $243.6 million in sales, growing 55% year over year. That crushed estimates from FactSet that called for $227.7 million.

#next #biopharmaceutical

Fans haven't seen much of Julia Roberts lately, but a source says Danny Moder is getting plenty of face time with the Oscar winner.
"Julia is in another one of her long work hiatuses and spending all of her time at home with Danny," the source explains to Star. "It puts Danny in the hot seat, because when Julia's home, she likes to have Danny around. If she isn't acting he can't just bail and go work on a film himself."
According to the source, the Pretty Woman icon, 58, has been extra clingy now that the three kids she and the cinematographer, 57, share — twins Hazel and Phinnaeus, 21, and son Henry, 19 — are out of the house.
"They're empty nesters and Julia refuses to go through that process alone," spills the source.
Instagram/Julia Roberts

#julia #source #oscar

Swansea City head coach Vitor Matos has said his side must "take care" of their impressive defensive record as they aim to challenge for promotion.
Championship leaders Swansea have conceded just once across their first five games of the season, fewer than any other team in the English Football League (EFL).
A 0-0 draw against Wrexham means the Swans have managed four clean sheets in their first five league games for the first time since the 1978-79 season.
"It's good, but we know it can change quite quickly. We all know how the league is and how the results are," Matos said after Saturday's Welsh derby.
"That [defensive record] is something that we need to take care of, of course. It's important for us."

#first #swansea #care #record

Vitor Matos says there is more to come from Swansea City after they moved a point clear at the top of the early-season Championship table thanks to a goalless draw with Wrexham.
Swansea were short of their best in possession but maintained their unbeaten start to the 2026-27 league campaign thanks to Lawrence Vigouroux's fourth successive clean sheet.
The Swans have taken 11 points from five second-tier games in what has been an encouraging start to the season.
But Matos believes there is progress to be made as his new-look squad contend with the packed Championship fixture list.
"I think being consistent is massive, keeping the desire is massive. Not getting frustrated when the game gets a little bit different from what we want is massive as well," the Swansea head coach said.

#start #wrexham

With a market cap of $138.2 billion, Bristol-Myers Squibb Company (BMY) is a global biopharmaceutical company that discovers, develops, manufactures, and markets innovative medicines worldwide. Its portfolio spans key therapeutic areas including oncology, hematology, immunology, cardiovascular disease, and neuroscience, with well-known products such as Opdivo, Eliquis, Revlimid, and Yervoy.
Companies valued at $10 billion or more are generally classified as "large-cap" stocks, and Bristol-Myers Squibb fits this criterion perfectly. The company serves patients through a broad commercial network that includes wholesalers, distributors, specialty pharmacies, hospitals, clinics, and government agencies.
Nvidia CEO Jensen Huang Says His $3.5 Billion MediaTek Deal Is 'Not Circular' Because 'They Do Their Own Business'
Strategy's Strategy Appears to Have Failed, and the Outlook of MSTR Stock Is Unfavorable
A Potential ***** eX Deal Could Meaningfully Accelerate Growth for Technip Stock

#company #bristol #squibb #Stock

On August 29, at the O2 Arena in London, Filip Hrgovic inflicted a shock defeat on heavyweight rising star Moses Itaumato become the new IBF heavyweight champion. Fans, fighters, and boxing coaches have had their say on what went wrong for the Brit, and Ryan Garcia is the latest to have his say when speaking to the media ahead of his September 12 WBC welterweight world ******* le defence against Conor Benn.
Moses Itauma (14-1, 12 KOs) entered the ring at the O2 Arena as a huge odds-on favourite against the experienced Croatian, Filip Hrgovic (21-1, 16 KOs). Itauma took no time to settle, quickly showcasing his blistering hand speed and impressive accuracy.
Despite the constant onslaught from Itauma, Hrgovic stood tall and took everything, and as the fight progressed, the Brit looked to be tiring. The Croat's right hand began to land with more regularity. The ninth round saw Itauma enter a state of barely being able to stand up, and Hrgovic let his hands go, with the towel coming in from Ben Davison just as the referee stepped in to wave the fight off. The O2 fell into stunned silence as Hrgovic and his team celebrated wildly that he was the new IBF heavyweight world champion.
"It's a marathon. Don't look too much into this defeat. Look into what you need to fix, for sure. But don't let it get you down completely. You were obviously the better fighter. You just weren't conditioned, and you just don't have enough experience at this current time to take that.
"But I don't think he did bad. He was doing pretty good, but…I don't know what was going on with his head. If you watch his interviews before, he's saying that he's not the best physcially right now (not sparred 12 rounds), nor mentally, but it will still be enough to beat Hrgovic. That's a really bad mindset," said Garcia, reflecting on Itauma's defeat.

#brit

CBF president Samir Xaud visited Pedro Pedrossian Stadium, known as Morenão, in Campo Grande on the morning of this Wednesday (2), on the eve of the inauguration of the Football Development Center of the State of Mato Grosso do Sul. Opened in 1971 and with a capacity of more than 40,000 fans, the main stage of football in Mato Grosso do Sul is receiving an investment of around R$ 1 million from the CBF to revitalize the pitch.
Xaud was accompanied by the president of the Mato Grosso do Sul Football Federation (FFMS), Estevâo Petrallás, who presented the stadium's history and detailed the progress of the work, as well as the president of the Mato Grosso Football Federation (FMF), Diogo Pécora, and the State Secretary of Tourism, Sports and Culture (Setesc), Alessandro Menezes.
CBF president Samir Xaud visited Morenão Stadium, which is receiving CBF investment to revitalize the pitchCredits: Rodrigo Moreira/CBF
In an interview with CBF TV, the CBF president commented on the importance of the institutional agenda in Mato Grosso do Sul and praised the history and renovation work at Morenão. The stadium has also hosted Brazil national team matches: a 1-1 draw with Paraguay on February 27, 1991, in a friendly; and a goalless draw with Venezuela on October 14, 2009, in the qualifiers for the 2010 World Cup.
"Today we began our institutional visit to Mato Grosso do Sul, continuing our work toward more participatory management and closer ties with the federations. We are here at Morenão, a stadium with a history shared by the entire state population, and where the CBF has provided funds to help revitalize the stadium, including replacing the pitch, irrigation and drainage. For us, it is another joy to work to help Brazilian football as a whole and the smaller federations," he said.

#mato #xaud #work #state

Ross Stewart looks set to miss Swansea City's next four matches because of a quad injury.
Scotland striker Stewart missed the Swans' Championship victory over Watford on Tuesday as well last Saturday's win at Derby County.
The 30-year-old has made only one substitute appearance, in the goalless draw with Sheffield United 11 days ago, since joining Swansea on a three-year contract last month.
Stewart is now expected to miss Swansea's home game against Wrexham on Saturday as well as the trip to Southampton – his former club – next Tuesday and fixtures against Burnley and Lincoln City prior to the international break at the end of the month.
"Ross had a soft tissue injury, not massive, but probably he can return in the international break," said Swansea head coach Vitor Matos.

#ross

Swansea head coach Vitor Matos is "really pleased" with their unbeaten start to the Championship season, but insisted they still have small improvements to make.
Goals from Joseph Opoku, Eom Ji-sung and Ronald gave Swansea a 3-0 win at Derby, taking Matos' charges to seven points from three games - their best start to a season since 2020-21.
The Swans won just seven of their 23 away Championship fixtures last season, but have taken six points from six at the start of this campaign.
Matos, into his second campaign in charge of Swansea, is pleased with their improved record on the road, and feels his players are enjoying themselves.
"There is still a lot to play [this season], but we are really pleased that we did a good job for our fans who were here," said Matos.

#season #pleased #championship #still

Al Michaels has reached a remarkable number of milestones, and Thursday night marked his crowning achievement. And it didn't have to do with his work as a legendary play-by-play announcer.
Michaels and his wife, Linda Anne Stamato, celebrated their 60th wedding anniversary on Thursday.
Thursday also brought the first Amazon Prime Video NFL broadcast of the 2026 football season, with the New England Patriots taking on the Cleveland Browns.
So, Michaels had play-by-play duties for Prime Video at Huntington Bank Field, and the Browns wished Al and Linda a happy 60th anniversary on the videoboard.
And with the second half about to start, Cleveland first-year head coach Todd Monken spoke with Prime Video sideline reporter Kaylee Hartung, who asked him about Browns quarterback Dillon Gabriel. Unprompted, Monken used the interview as an opportunity to deliver a message to Al and Linda.

#anniversary

Spyre Therapeutics (SYRE) took a hit Wednesday after its experimental rheumatoid arthritis treatment failed to pass muster in midstage testing.
But **** ysts are far more interested in Spyre's inflammatory bowel disease drugs. These conditions include ulcerative colitis and Crohn's disease.
"Even excluding all non-UC (ulcerative colitis) indications, our PT (price target) would remain at ~$115, well above current trading levels," Wedbush **** yst David Nierengarten said in a client note. "While we view the RS (rheumatoid arthritis) results as disappointing, we see limited impact to our core IBD-driven (inflammatory bowel disease) thesis."
Still, Spyre stock fell 1.8%, closing at 93.61. Shares are highly rated with a strong IBD Digital Relative Strength Rating of 98, putting the stock's 12-month performance in the leading 2% of all stocks.
Spyre's drug, dubbed SPY072, actually showed some effectiveness in patients with rheumatoid arthritis. But the results didn't pass the company's internal bar for advancement. Spyre is still testing SPY072 in other rheumatology indications, including psoriatic arthritis and axial spondyloarthritis.

#arthritis #testing #bowel

Conservatives piled on Democratic Rep. Debbie Dingell after she argued Republicans are trying to make Michigan's Senate race about socialist streamer Hasan Piker, with critics saying her frustration only highlighted a political vulnerability for Democrats.
"Debbie Dingell CRASHES OUT over terrorist-sympathizer Hasan Piker who has called to kill Republicans,'" wrote the Republican National Committee's research account.
Critics took aim at Dingell for campaigning with Michigan Democratic Senate candidate Abdul El-Sayed after she told reporters she was done answering questions about Piker, whose past inflammatory remarks have drawn renewed scrutiny and pressure on Democrats to respond.
Democrats Condemning Hasan Piker As Backlash Spreads Through Party
"YIKES: Democrats are getting tired of defending Abdul El-Sayed for his antisemitic campaign surrogate Hasan Piker Rep. Debbie Dingell: 'I am DONE. So don't any reporter ask me again about Hasan Piker.' El-Sayed has yet to disavow Piker," wrote Senate Republicans on X.

#dingell #senate

On August 13, Nektar Therapeutics (NASDAQ:NKTR) held its second-quarter earnings call and laid out where its lead drug candidate stands after years of development. Rezpegaldesleukin, known as rezpeg, is now enrolling patients in Phase 3 trials for two separate autoimmune conditions, atopic dermatitis and alopecia areata. Management framed the quarter around two numbers that matter most to investors right now: a $1.02 billion cash balance that provides a runway into 2028, and a drug program that finally has late-stage data on the calendar.
Nektar's Phase 3 program for atopic dermatitis, called ZENITH AD, began randomizing patients in July 2026 across two pivotal studies, each enrolling 510 adolescent and adult patients. A third study in patients who have already tried other treatments is set to start by the end of September 2026. Management expects top-line data from the first studies in mid-2028, with a Biologics License Application submission to follow in 2029 if results hold up. After an end-of-Phase 2 meeting with the FDA, Nektar also finalized a single registrational Phase 3 study for alopecia areata, called ZENITH AA, which will enroll 850 patients and use a SALT score of 20 or less at week 52, meaning 80% or more scalp hair coverage, as its primary endpoint.
The case for rezpeg goes beyond trial design. CEO Howard Robin noted that roughly 15 million people in the U.S. have moderate to severe atopic dermatitis, and fewer than 10% currently get a systemic therapy, leaving room for the market itself to grow. He also pointed out that about half of patients on IL-13 drugs such as Dupixent either stop responding or never respond at all. In alopecia areata, where JAK inhibitors carry boxed warnings that keep many dermatologists away, the market for approved treatments is still projected to reach $5 billion by 2033. Nektar's own market research found that 150 of 151 physicians surveyed preferred rezpeg's short-lived injection site reactions over the longer-lasting conjunctivitis tied to current options, a result management used to argue rezpeg could compete across first, second, and third-line patients.
None of this comes cheap. Nektar's operating loss widened to $42.3 million in the second quarter, up from $36.2 million a year earlier, and the net loss came in at $40.6 million, or $1.23 per share. Research and development spending is set to climb further, with full-year guidance now at $210 million to $230 million as the Phase 3 programs and manufacturing activities ramp up. The company's only revenue right now is $10.1 million in noncash royalty income, down from $11.2 million a year ago, and full-year revenue guidance tops out at $45 million. That gap between spending and revenue is why Nektar leaned on a public stock offering that raised $373.8 million in gross proceeds in April 2026, a move that keeps the lights on but also dilutes existing shareholders.

#quarter

Stockard Channing, 82, made her first red carpet appearance in two years on Wednesday, just days after admitting she's become a "recluse" since the death of her partner in 2014.
The 82-year-old actor attended the European premiere of Practical Magic 2 at Odeon Luxe Leicester Square in London on Wednesday. She reprises her role as Frances "Fran" Owens, the witch aunt of Sally Owens (played by Sandra Bullock) and Gillian Owens (played by Nicole Kidman) in the fantasy sequel.
It was her first time back on the red carpet since a low-key appearance at the press night for **** o, Dolly! at the London Palladium in July 2024.
It comes after Channing told The Sunday Times about her move to London from Maine following the death of her partner, cinematographer Daniel Gillham, in 2014. The couple had been together for 24 years after meeting on the set of World War II drama A Time of Destiny.
"I've lived alone since I lost Daniel and I'm happy being a recluse," she said.

#since

Hyundai Department Store is preparing to launch COOD, which it describes as South Korea's first speciality select shop built around derma beauty as its core concept.
According to a translated version of the Yonhap News Agency report, the inaugural outlet will open on the basement level of the company's Pangyo store on 18 September.
Spanning approximately 165.28m², the store will stock more than 60 derma beauty brands.
Derma beauty, a term combining "dermatology" and "beauty", describes products created through research and development involving input from medical and bio-science specialists, aimed at enhancing skin function.
Hyundai Department Store noted that although derma beauty items have already been sold within established beauty retailers, COOD represents the sector's first standalone store format centred specifically on this category.

#beauty